Skip to navigation Skip to content

Participe en una prueba clínica

Sin la participación de personas con esclerosis múltiple, sería imposible desarrollar nuevos y mejores tratamientos, y otras intervenciones.

Share

Nos esforzamos por traducir cada vez más contenido al español, pero algunos de los enlaces incluidos aquí van a páginas en inglés. Si usa el traductor de su navegador, tenga en cuenta que es posible que la traducción no sea exacta.

Pruebas clínicas cercanas

¿Tiene interés en las pruebas clínicas? Simplemente busque por estado, tipo de esclerosis múltiple o palabra clave, y vea qué está sucediendo en su zona.

v
  1. Research Study: Mechanisms of Low Physical Work Capacity, Fatigue, and Reduced Mobility

    You are being asked to be a subject in a research study about blood flow regulation during exercise and how that may affect work capacity (the ability to perform exercise). This study will examine cardiac output (how much blood your heart can pump each minute) during a treadmi...
  2. Clinical Trial: Immune responses to COVID vaccines in people with MS on ocrelizumab

    It is not know whether people receiving ocrelizumab for MS mount adequate immune responses to COVID-19 vaccine. The study is designed to investigate B-cell and T-cell responses to COVID-19 vaccination in patients treated with Ocrevus.  There are 5 visits for this study. All...
  3. Clinical Trial: Ofatumumab for Patients with Relapsing Multiple Sclerosis

    MS study evaluating the continued effectiveness, safety and tolerability of Ofatumumab in adults, between the ages 18-60, with relapsing multiple sclerosis who are transitioning from traditional anti-CD20 therapy. Click on this link to answer a few questions to see if you q...
  4. Clinical Trial: Ozanimod to Improve Cognitive Function

     Investigators are recruiting 250 people with relapsing forms of MS for a clinical trial to determine if ozanimod (Zeposia ® , Bristol Myers Squibb) improves cognitive functions, specifically information processing speed. The study is funded by Celgene. Read more
  5. Clinical Trial: Ofatumumab

    MS study to evaluate the effectiveness of ofatumumab after transitioning from oral therapy, in adults 18 to 60 with relapsing MS experiencing breakthrough disease.  Study participation includes in-person visits, blood draws, MRI appointments, and use of electronic devices and ...
  6. Clinical Trial: Higher dose of ocrelizumab in PPMS

    An open-label, single-arm study to evaluate the effectiveness and safety of ocrelizumab in people with primary progressive MS. Subjects participating in the study will complete the following procedures: study visits, blood draw/sample collections, MRI Scans, potential lumbar p...
  7. Clinical Trial: Higher dose of ocrelizumab in PPMS

    An open-label, single-arm study to evaluate the effectiveness and safety of ocrelizumab in people with primary progressive MS. Subjects participating in the study will complete the following procedures: study visits, blood draw/sample collections, MRI Scans, potential lumbar p...
  8. Clinical Trial: Ozanimod for Cognitive Function

    This is a multicenter, single-arm, open-label study to describe the change from baseline in cognitive processing speed in subjects with relapsing multiple sclerosis (RMS) treated with ozanimod HCl 1 mg at 3 years. All enrolled subjects will receive orally administered ozanimod...
  9. Clinical Trial: Treadmill training to reduce falls

    Falls present a serious challenge facing individuals affected by multiple sclerosis. This study aims to examine if and to what extent slip-based training can reduce the risk of falls for people with multiple sclerosis. The researchers are seeking adults (18-65 years old) with ...
  10. Clinical Trial: Employment-Related Telephone Intervention for Pain Study (E-TIPS)

    The E-TIPS trial will evaluate an evidence-based, telehealth pain self-management intervention compared to standard care (a waitlist) for chronic pain in adults with multiple sclerosis who are employed. Participants from anywhere in the US will be randomly assigned to either E...
  11.  |<  <  1 - 2 - 3 - 4 - 5 - 6 - 7 - 8 - 9 - 10  >  >| 

Share


© 2023 La Sociedad Nacional de Esclerosis Múltiple es una entidad sin fines de lucro de tipo 501(c)3 y exenta de impuestos. Su número de identificación (EIN por su sigla en inglés) es 13-5661935.